MA34173B1 - Hhétérobiaryl-cyclohexyl-tétraazabenzo[e]azulènes - Google Patents
Hhétérobiaryl-cyclohexyl-tétraazabenzo[e]azulènesInfo
- Publication number
- MA34173B1 MA34173B1 MA35327A MA35327A MA34173B1 MA 34173 B1 MA34173 B1 MA 34173B1 MA 35327 A MA35327 A MA 35327A MA 35327 A MA35327 A MA 35327A MA 34173 B1 MA34173 B1 MA 34173B1
- Authority
- MA
- Morocco
- Prior art keywords
- disorders
- azulenes
- cyclohexyl
- relates
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
LA PRÉSENTE INVENTION PORTE SUR DES HÉTÉROBIARYL-CYCLOHEXYL-TÉTRAAZABENZO[E]AZULÈNES DE FORMULE (I), DANS LAQUELLE R1, R2 ET R3 SONT TELS QUE DÉCRITS DANS LA DESCRIPTION. LES COMPOSÉS SELON L'INVENTION SERVENT DE MODULATEURS DU RÉCEPTEUR V1A ET EN PARTICULIER D'ANTAGONISTES DU RÉCEPTEUR V1A. L'INVENTION PORTE ÉGALEMENT SUR LEUR FABRICATION, SUR DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET SUR LEUR UTILISATION COMME MÉDICAMENTS. LES COMPOSÉS ACTIFS DE LA PRÉSENTE INVENTION SONT UTILES COMME AGENTS THÉRAPEUTIQUES AGISSANT DE FAÇON PÉRIPHÉRIQUE ET CENTRALE DANS LES AFFECTIONS DE DYSMÉNORRHÉE, DE DISFONCTIONNEMENT SEXUEL MASCULIN OU FÉMININ, D'HYPERTENSION, D'INSUFFISANCE CARDIAQUE CHRONIQUE, DE SÉCRÉTION INAPPROPRIÉE DE VASOPRESSINE, DE CIRRHOSE DU FOIE, DE SYNDROME NÉPHROTIQUE, D'ANXIÉTÉ, DE TROUBLES DÉPRESSIFS, DE TROUBLES OBSESSIONNELS-COMPULSIFS, DE TROUBLES DU SPECTRE AUTISTIQUE, DE SCHIZOPHRÉNIE ET DE COMPORTEMENT AGRESSIF.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10161043 | 2010-04-26 | ||
| PCT/EP2011/056391 WO2011134877A1 (fr) | 2010-04-26 | 2011-04-21 | Hétérobiaryl-cyclohexyl-tétraazabenzo[e]azulènes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA34173B1 true MA34173B1 (fr) | 2013-04-03 |
Family
ID=43991411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA35327A MA34173B1 (fr) | 2010-04-26 | 2011-04-21 | Hhétérobiaryl-cyclohexyl-tétraazabenzo[e]azulènes |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US8481528B2 (fr) |
| EP (1) | EP2571879B1 (fr) |
| JP (1) | JP5579925B2 (fr) |
| KR (1) | KR101506778B1 (fr) |
| CN (1) | CN102858778B (fr) |
| AR (1) | AR081182A1 (fr) |
| AU (1) | AU2011246553B2 (fr) |
| BR (1) | BR112012027392A2 (fr) |
| CA (1) | CA2794824A1 (fr) |
| CL (1) | CL2012002954A1 (fr) |
| CO (1) | CO6612268A2 (fr) |
| CR (1) | CR20120515A (fr) |
| CY (1) | CY1117145T1 (fr) |
| DK (1) | DK2571879T3 (fr) |
| EA (1) | EA021495B1 (fr) |
| EC (1) | ECSP12012209A (fr) |
| ES (1) | ES2553246T3 (fr) |
| HK (1) | HK1176933A1 (fr) |
| HR (1) | HRP20160051T1 (fr) |
| HU (1) | HUE028018T2 (fr) |
| IL (1) | IL222408A (fr) |
| MA (1) | MA34173B1 (fr) |
| MX (1) | MX2012012517A (fr) |
| MY (1) | MY160977A (fr) |
| NZ (1) | NZ602663A (fr) |
| PE (1) | PE20130189A1 (fr) |
| PL (1) | PL2571879T3 (fr) |
| PT (1) | PT2571879E (fr) |
| RS (1) | RS54418B1 (fr) |
| SG (1) | SG184533A1 (fr) |
| SI (1) | SI2571879T1 (fr) |
| TW (1) | TWI419891B (fr) |
| UA (1) | UA110031C2 (fr) |
| WO (1) | WO2011134877A1 (fr) |
| ZA (1) | ZA201207693B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2356123T3 (pl) * | 2008-11-13 | 2013-03-29 | Hoffmann La Roche | Spiro-5,6-dihudro-4h-2,3,5,10b- tetraazabenzo[e]azuleny |
| CA2739900C (fr) * | 2008-11-18 | 2016-11-08 | F. Hoffmann-La Roche Ag | Alkylcyclohexylethers de dihydrotetrazabenzoazulenes |
| ES2431279T3 (es) | 2008-11-28 | 2013-11-25 | F. Hoffmann-La Roche Ag | Arilciclohexiléteres de dihidro-tetraazabenzoazulenos para uso como antagonistas del receptor V1A de la vasopresina |
| US8420633B2 (en) | 2010-03-31 | 2013-04-16 | Hoffmann-La Roche Inc. | Aryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8461151B2 (en) | 2010-04-13 | 2013-06-11 | Hoffmann-La Roche Inc. | Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes |
| US8481528B2 (en) | 2010-04-26 | 2013-07-09 | Hoffmann-La Roche Inc. | Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8513238B2 (en) | 2010-05-10 | 2013-08-20 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes |
| CN115246781B (zh) * | 2021-04-28 | 2024-03-29 | 南京正大天晴制药有限公司 | 一种沙芬酰胺的制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5516774A (en) * | 1993-07-29 | 1996-05-14 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
| US5521173A (en) | 1995-01-17 | 1996-05-28 | American Home Products Corporation | Tricyclic benzazepine vasopressin antagonists |
| AU756959B2 (en) * | 1997-07-30 | 2003-01-30 | Wyeth | Tricyclic vasopressin agonists |
| CZ302647B6 (cs) | 1999-01-19 | 2011-08-17 | Ortho-Mcneil Pharmaceutical, Inc. | Tricyklický benzodiazepin, farmaceutický prípravek s jeho obsahem a meziprodukty pro jeho prípravu |
| US7109193B2 (en) * | 2001-04-12 | 2006-09-19 | Wyeth | Tricyclic diazepines tocolytic oxytocin receptor antagonists |
| US7022699B2 (en) | 2001-04-12 | 2006-04-04 | Wyeth | Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators |
| GB0303852D0 (en) | 2003-02-19 | 2003-03-26 | Pfizer Ltd | Triazole compounds useful in therapy |
| EA009460B1 (ru) * | 2003-02-19 | 2007-12-28 | Пфайзер Инк. | Триазольные соединения, полезные в терапии |
| GB0400700D0 (en) | 2004-01-13 | 2004-02-18 | Pfizer Ltd | Compounds useful in therapy |
| CN1950374A (zh) | 2004-05-25 | 2007-04-18 | 辉瑞产品公司 | 四氮杂苯并[e]甘菊环衍生物及其类似物 |
| KR100840852B1 (ko) | 2004-05-25 | 2008-06-23 | 화이자 프로덕츠 인크. | 테트라아자벤조[ｅ]아줄렌 유도체 및 이의 유사체 |
| GB0412874D0 (en) * | 2004-06-09 | 2004-07-14 | Pfizer Ltd | Novel pharmaceuticals |
| EP1632494A1 (fr) | 2004-08-24 | 2006-03-08 | Ferring B.V. | Antagonistes de la v1a vasopressine |
| MX2007002248A (es) | 2004-08-25 | 2008-10-02 | Pfizer | Triazolobenzodiazepinas y su uso como antagonistas de vasopresina. |
| JP2008539220A (ja) | 2005-04-26 | 2008-11-13 | ファイザー・リミテッド | バソプレシンアンタゴニストとしてのトリアゾール誘導体 |
| US20080234252A1 (en) | 2005-05-18 | 2008-09-25 | Pfizer Inc | Compounds Useful in Therapy |
| WO2008084005A1 (fr) | 2007-01-12 | 2008-07-17 | F. Hoffmann-La Roche Ag | Dérivés de spiropipéridine glycinamide |
| CA2739900C (fr) | 2008-11-18 | 2016-11-08 | F. Hoffmann-La Roche Ag | Alkylcyclohexylethers de dihydrotetrazabenzoazulenes |
| US8420633B2 (en) | 2010-03-31 | 2013-04-16 | Hoffmann-La Roche Inc. | Aryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8461151B2 (en) | 2010-04-13 | 2013-06-11 | Hoffmann-La Roche Inc. | Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes |
| US8481528B2 (en) | 2010-04-26 | 2013-07-09 | Hoffmann-La Roche Inc. | Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8513238B2 (en) | 2010-05-10 | 2013-08-20 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes |
-
2011
- 2011-04-19 US US13/089,354 patent/US8481528B2/en active Active
- 2011-04-21 UA UAA201213289A patent/UA110031C2/uk unknown
- 2011-04-21 SI SI201130662T patent/SI2571879T1/sl unknown
- 2011-04-21 JP JP2013506597A patent/JP5579925B2/ja not_active Expired - Fee Related
- 2011-04-21 MY MYPI2012004626A patent/MY160977A/en unknown
- 2011-04-21 PL PL11715545T patent/PL2571879T3/pl unknown
- 2011-04-21 AU AU2011246553A patent/AU2011246553B2/en not_active Ceased
- 2011-04-21 EA EA201291109A patent/EA021495B1/ru not_active IP Right Cessation
- 2011-04-21 PT PT117155457T patent/PT2571879E/pt unknown
- 2011-04-21 NZ NZ602663A patent/NZ602663A/xx not_active IP Right Cessation
- 2011-04-21 CN CN201180021078.6A patent/CN102858778B/zh not_active Expired - Fee Related
- 2011-04-21 BR BR112012027392A patent/BR112012027392A2/pt not_active IP Right Cessation
- 2011-04-21 SG SG2012075149A patent/SG184533A1/en unknown
- 2011-04-21 KR KR1020127030686A patent/KR101506778B1/ko not_active IP Right Cessation
- 2011-04-21 MX MX2012012517A patent/MX2012012517A/es active IP Right Grant
- 2011-04-21 PE PE2012002067A patent/PE20130189A1/es not_active Application Discontinuation
- 2011-04-21 RS RS20150763A patent/RS54418B1/en unknown
- 2011-04-21 DK DK11715545.7T patent/DK2571879T3/en active
- 2011-04-21 HU HUE11715545A patent/HUE028018T2/en unknown
- 2011-04-21 CA CA2794824A patent/CA2794824A1/fr not_active Abandoned
- 2011-04-21 ES ES11715545.7T patent/ES2553246T3/es active Active
- 2011-04-21 WO PCT/EP2011/056391 patent/WO2011134877A1/fr active Application Filing
- 2011-04-21 EP EP11715545.7A patent/EP2571879B1/fr not_active Not-in-force
- 2011-04-21 MA MA35327A patent/MA34173B1/fr unknown
- 2011-04-25 AR ARP110101400A patent/AR081182A1/es unknown
- 2011-04-25 TW TW100114337A patent/TWI419891B/zh not_active IP Right Cessation
-
2012
- 2012-09-28 CO CO12170756A patent/CO6612268A2/es not_active Application Discontinuation
- 2012-10-02 EC ECSP12012209 patent/ECSP12012209A/es unknown
- 2012-10-11 IL IL222408A patent/IL222408A/en active IP Right Grant
- 2012-10-11 CR CR20120515A patent/CR20120515A/es unknown
- 2012-10-12 ZA ZA2012/07693A patent/ZA201207693B/en unknown
- 2012-10-23 CL CL2012002954A patent/CL2012002954A1/es unknown
-
2013
- 2013-04-12 HK HK13104455.5A patent/HK1176933A1/xx not_active IP Right Cessation
-
2016
- 2016-01-15 HR HRP20160051TT patent/HRP20160051T1/hr unknown
- 2016-01-19 CY CY20161100048T patent/CY1117145T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA34174B1 (fr) | Hetéroaryl-cyclohexyl-tétraazabenzo[e)azulènes comme antagonistes des récepteurs de la vasopressine v1a | |
| MA34173B1 (fr) | Hhétérobiaryl-cyclohexyl-tétraazabenzo[e]azulènes | |
| MA34252B1 (fr) | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes | |
| MA32781B1 (fr) | Arycyclohexylethers de dihydrotetrazabenzoazulenes pour emploi en tant qu'antagonistes du recepteur v1a de la vasopressine | |
| MA33920B1 (fr) | Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide | |
| MA34147B1 (fr) | Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales | |
| EA201170705A1 (ru) | Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1 | |
| MA35246B1 (fr) | 1,3-oxazines en tant qu'inhibiteurs de bace1 et/ou de bace2 | |
| MA35576B1 (fr) | Nouveaux composés | |
| MA30539B1 (fr) | Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38. | |
| MX2009006921A (es) | Derivados azaespiro. | |
| MA29411B1 (fr) | 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa | |
| MA35193B1 (fr) | Halogeno-alkyl-1,3 oxazines en tant qu'inhibiteurs de bace1 et/ou bace2 | |
| MA37764A1 (fr) | Composés n-alkyltriazole utilisés comme antagonistes de lpar | |
| MA35191B1 (fr) | Spiro-[1,3]-oxazines et spiro-[1,4]-oxazepines en tant qu'inhibiteurs de baec1 et/ou bace2 | |
| MA30696B1 (fr) | Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique | |
| MA34650B1 (fr) | Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane | |
| MA31117B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
| MA32598B1 (fr) | Nouveaux benzamides, leur preparation et leur utilisation comme medicaments | |
| MA33302B1 (fr) | 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale | |
| MX2013008478A (es) | 1, 4 riazepinas/sulfonas como inhibidores de beta secretasa 1 (base1) y/o beta secretasa 2 (bace2). | |
| MA35748B1 (fr) | Fluorométhyl-5,6-dihydro-4h-[1,3]oxazines | |
| MA35271B1 (fr) | Antagonistes de trpm8 et leur utilisation dans des traitements | |
| TNSN08137A1 (fr) | Derives de carboxamides servant d'antagonistes des recepteurs muscariniques | |
| MA35286B1 (fr) | Phényl-3-aza-bicyclo[3.1.0]hex-3-yl-méthanones et leur utilisation en tant que médicament |